Streetbeat News

VEXTF

Vext Science Inc.

https://www.vapenmj.com/

Industry

Medicinal and Botanical Manufacturing

Open

0.14

Mkt cap

34M

Volume

15K

High

0.14

P/E Ratio

4.67

52-wk high

0.32

Low

0.14

Div yield

N/A

52-wk low

0.11

Vext Science, Inc. (VEXTF) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included CEO Eric Offenberger and CFO Trevor Smith.

Portfolio Pulse from

November 22, 2024 | 9:45 pm

Vext Science, Inc., a U.S.-based cannabis operator, will release its Q3 2024 financial results on November 21, 2024. The company will also host a conference call and webcast on the same day.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

Viridian Capital Advisors highlights the importance of considering hidden debt in cannabis company valuations. Companies like Planet 13 Holdings and MariMed saw valuation increases when hidden debts were factored in, while others like Schwazze and Green Thumb Industries showed minimal changes, indicating cleaner balance sheets.

Portfolio Pulse from Nicolás Jose Rodriguez

September 22, 2024 | 4:19 pm

Vext Science Inc. (OTC:VEXTF) is poised to benefit from Ohio's burgeoning recreational cannabis market, despite facing challenges in Arizona. Ohio's market launch has led to a significant sales increase, positioning Vext as a strong contender among multi-state operators. However, Vext's overall sales declined due to issues in Arizona. Analyst Pablo Zuanic projects a potential fivefold increase in Vext's valuation by late 2025.

Portfolio Pulse from Nicolás Jose Rodriguez

September 07, 2024 | 8:21 pm

Arizona's cannabis market is experiencing a decline in sales despite strong asset valuations. Sales have dropped significantly from their peak in March 2023, with both adult-use and medical marijuana sectors affected. Increased competition and falling prices due to market saturation are contributing factors. Vext Science Inc. reported a steep decline in dispensary net sales, while Verano Holdings Corp. acquired three Arizona subsidiaries, indicating continued interest in the market.

Portfolio Pulse from Juan Spínelli

August 23, 2024 | 2:56 am

The cannabis and psychedelics industries are experiencing significant executive changes. Canopy Growth's CEO David Klein will retire in 2025, while Curaleaf's Boris Jordan will become CEO in 2024. Village Farms extended CEO Michael DeGiglio's contract, and MariMed appointed Mario Pinho as CFO. Several companies, including Aurora Cannabis and Agrify, have made board changes.

Portfolio Pulse from Jelena Martinovic

August 21, 2024 | 2:35 pm

Vext Science, Inc. reported an 8% YoY revenue drop in Q2 2024, but anticipates growth from Ohio's new recreational cannabis market. Despite financial setbacks, Vext is optimistic about its Ohio operations and future performance.

Portfolio Pulse from Jelena Martinovic

August 20, 2024 | 1:27 pm

Vext Science, Auxly Cannabis Group, and MediPharm Labs are set to release their Q2 2024 financial results in mid-August. Vext Science is highlighted for its significant growth potential, especially in the Ohio market. Auxly has shown record-breaking Q1 results and significant debt conversion into equity. MediPharm has entered a licensing agreement for advanced cannabis products and reported a 67% revenue increase in Q1 2024.

Portfolio Pulse from Jelena Martinovic

August 09, 2024 | 3:37 pm

As Ohio begins recreational cannabis sales on August 6, Pablo Zuanic of Zuanic & Associates has initiated coverage of Vext Science (OTC:VEXTF) with an Overweight rating, citing significant growth potential. Zuanic projects Vext's EBITDA could grow six-fold by CY26. The Ohio market is expected to reach $2.36 billion by 2026. Despite trading in line with the MSO average, Vext's stock valuation does not yet reflect the expected EBITDA ramp. Other MSOs mentioned include Acreage (OTCQX:ACRHF), Cannabist (CSE:CCHW), Ascend (OTC:AAWH), Cresco (OTC:CRLBF), Green Thumb (OTCQX:GTBIF), and MariMed (OTCQB:MRMD).

Portfolio Pulse from Nicolás Jose Rodriguez

August 05, 2024 | 11:52 pm

Several cannabis companies are approaching significant debt maturities, which could impact their financial stability and investor portfolios. Curaleaf, Cresco Labs, Green Thumb, and Ascend Wellness face substantial refinancing risks, while Vext Science, Jushi Holdings, and Cansortium have relatively moderate debt challenges. Investors should monitor these developments closely.

Portfolio Pulse from Nicolás Jose Rodriguez

June 25, 2024 | 10:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.